1. Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer
   Hong Fang et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef
2. Ancillary Studies for Serous Fluids
   Lukas Bubendorf et al, 2020, The International System for Serous Fluid Cytopathology CrossRef
3. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma
   Ying Liu et al, 2016, Radiology CrossRef
4. Sensitive quantitation of ESR1 mutations in cell-free DNA from breast cancer patients using base-specific invasive reaction assisted qPCR
   Chen Wang et al, 2021, Journal of Pharmaceutical and Biomedical Analysis CrossRef
5. Personalized drug testing in a patient with non-small-cell lung cancer using cultured cancer cells from pleural effusion
   Ming Wu et al, 2020, Journal of International Medical Research CrossRef
6. High Feasibility of Liquid-Based Cytological Samples for Detection of EGFR Mutations in Chinese Patients with NSCLC
   Chun-Yan Wu et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef
7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations
   Jing-Hui Lin et al, 2017, Oncotarget CrossRef
8. Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival
   Navneet Singh et al, 2016, Lung India CrossRef
9. EGFR mutations in non-small cell lung cancer: an audit from West China Hospital
   Yuan Tang et al, 2016, Expert Review of Molecular Diagnostics CrossRef
10. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient
    Yi Wang et al, 2018, Gene CrossRef
11. Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis
    Qi Feng et al, 2017, Oncotarget CrossRef
12. Comparison of Epidermal Growth Factor Receptor Mutations between Primary Tumors and Lymph Nodes in Non-small Cell Lung Cancer: a Review and Meta-analysis of Published Data
    Feng Wang et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef
13. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA
    Zheng Xiang et al, 2018, Analytical and Bioanalytical Chemistry CrossRef
14. Methodological comparison of the allele refractory mutation system and direct sequencing for detecting EGFR mutations in NSCLC, and the association of EGFR mutations with patient characteristics
    Minmin Wu et al, 2018, Oncology Letters CrossRef
15. Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay
    Sanpeng Xu et al, 2016, Oncology Letters CrossRef
16. Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFR‑tyrosine kinase inhibitor treatment in patients with non‑small cell lung cancer from different ethnic groups
    Qiao Zhang et al, 2020, Experimental and Therapeutic Medicine CrossRef